Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375013 | 1.00 | KAT2B (0.58) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL10622798 | 0.91 | KAT2B (0.72) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL8107611 | 0.90 | MAPT (0.60) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL2228520 | 0.89 | KAT2B (0.66) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL30413993 | 0.88 | KAT2B (0.64) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL2228171 | 0.88 | KAT2B (0.64) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL17923845 | 0.88 | KAT2B (0.64) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL4557828 | 0.88 | KAT2B (0.64) | KAT2BMAPTPOLBPKMKDM4E | |
| Hydrochloric Acid SCHEMBL4699216 | 0.87 | KAT2B (0.65) | KAT2BMAPTPOLBPKMKDM4E | |
| SCHEMBL8147273 | 0.87 | MAPT (0.65) | KAT2BMAPTPOLBPKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109477844-A | For detecting the chemiluminescence biosensor of coagulation factor | 李知勋 | 2019-03-15 | — | — | CN | claimed |
| JP-60169495-A | — | — | None | — | — | JP | disclosed |
| US-20250115546-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | UNIV TEXAS (US) | 2025-04-10 | — | — | US | disclosed |
| US-12084403-B2 | Linkers for antibody drug conjugates | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4335460-A2 | COMPOSITIONS AND METHODS FOR TREATING GRANULOMATOSIS WITH POLYANGIITIS | Canem Holdings, LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240059647-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | UNIV TEXAS (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3253406-B1 | COMPOSITIONS FOR TREATING GRANULOMATOSIS WITH POLYANGIITIS | CANEM HOLDINGS LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230241189-A1 | Compositions and Methods for Treating Granulomatosis with Polyangiitis | CANEM HOLDINGS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-11629122-B2 | Linkers for antibody drug conjugates | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-18 | — | — | US | disclosed |
| CN-110596365-B | Method and kit for determining cholesterol loading capacity of lipoprotein | 希森美康株式会社 | 2022-11-15 | — | — | CN | disclosed |
| US-6407206-B1 | PEPTIDE SUBSTRATE AND OLIGOPEPTIDES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1212619-A1 | SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS | Xenoport, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1089988-A1 | FLUOROPHENYL RESIN COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2001020331-A1 | SUBSTRATES AND SCREENING METHODS FOR TRANSPORT PROTEINS | XENOPORT, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-1046650-A1 | PEPTIDES, METHOD FOR ASSAYING HUMAN PEPSINOGEN II or HUMAN PEPSIN II, AND ASSAYING KIT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999067228-A1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0959078-A1 | PEPTIDES, METHODS FOR ASSAYING HUMAN PEPSINOGEN I OR HUMAN PEPSIN I, AND ASSAY KITS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-11-24 | — | — | EP | disclosed |
| JP-S60169495-A | MODIFIED DNA AND USE THEREOF | TAKEDA CHEM IND LTD | 1985-09-02 | — | — | JP | disclosed |
| US-4185090-A | PARTIALLY DETOXIFIED LIPOPOLYSACCHARIDE COVALENTY COUPLED TO A PROTEIN ANTIGEN | ABBOTT LABORATORIES (US) | 1980-01-22 | — | — | US | disclosed |
| US-4057685-A | Chemically modified endotoxin immunizing agent | ABBOTT LABORATORIES (US) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115546-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | CD47, EPCAM, SDCBP | KAT2B 2235/4885MAPT 513/4885POLB 3987/4885 |
| US-12084403-B2 | Linkers for antibody drug conjugates | CD47, EPCAM, SDCBP | KAT2B 2235/4885MAPT 513/4885POLB 3987/4885 |
| US-20240059647-A1 | LINKERS FOR ANTIBODY DRUG CONJUGATES | CD47, EPCAM, SDCBP | KAT2B 2235/4885MAPT 513/4885POLB 3987/4885 |
| US-11629122-B2 | Linkers for antibody drug conjugates | CD47, EPCAM, FCGRT | KAT2B 1974/4885MAPT 589/4885POLB 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.